Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclohexane SCHEMBL1228423 | 0.94 | CYP3A4 (0.52) | CYP3A4TSHRPIK3CAALDH1A1GABRA1 | |
| SCHEMBL598930 | 0.82 | LMNA (0.57) | CYP3A4TSHRPIK3CAGABRA1GABRG2 | |
| SCHEMBL28485960 | 0.79 | LMNA (0.55) | CYP3A4TSHRPIK3CAGABRA1GABRG2 | |
| SCHEMBL11807994 | 0.79 | CYP3A4 (0.56) | CYP3A4TSHRPIK3CAALDH1A1GABRA1 | |
| SCHEMBL28749904 | 0.79 | CYP3A4 (0.50) | CYP3A4TSHRPIK3CAALDH1A1GABRA1 | |
| SCHEMBL9078471 | 0.79 | CYP3A4 (0.50) | CYP3A4TSHRPIK3CAALDH1A1GABRA1 | |
| SCHEMBL2907892 | 0.78 | CYP3A4 (0.42) | CYP3A4TSHRPIK3CAALDH1A1GABRA1 | |
| SCHEMBL104522 | 0.78 | CYP3A4 (0.48) | CYP3A4TSHRPIK3CAALDH1A1GABRA1 | |
| SCHEMBL29407112 | 0.78 | CYP3A4 (0.48) | CYP3A4TSHRPIK3CAALDH1A1GABRA1 | |
| SCHEMBL104513 | 0.77 | GABRA1 (0.50) | CYP3A4TSHRPIK3CAALDH1A1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5453478-A | Diamines for chain extension of polyurethanes, polyamides and polyimides | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1995-09-26 | — | — | US | claimed |
| WO-2021083167-A1 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-05-06 | — | — | WO | disclosed |
| EP-3772517-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING SAME, AND DIAGNOSTIC COMPOSITION INCLUDING SAME | Samsung Electronics Co., Ltd. (KR) | 2021-02-10 | — | — | EP | disclosed |
| US-20180221379-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2015-12-17 | — | — | US | disclosed |
| US-8623889-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-8476430-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20110124640-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-26 | — | — | US | disclosed |
| US-20050085522-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
| CN-1491216-A | Novel alkylphenylimidazolidine derivatives for the treatment of urinary incontinence | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-04-21 | — | — | CN | disclosed |
| EP-1362038-A1 | NOVEL ALKYL PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-11-19 | — | — | EP | disclosed |
| US-20020169193-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG | 2002-11-14 | — | — | US | disclosed |
| WO-2002064570-A1 | NOVEL ALKYL PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | CYP3A4 4648/4885TSHR 70/4885PIK3CA 1698/4885 |
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | RTF2, REV1, PCNA | CYP3A4 832/4885TSHR 4441/4885PIK3CA 1523/4885 |
| US-20020169193-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | AGTR2, ADRB2, REN | CYP3A4 2910/4885TSHR 1979/4885PIK3CA 3475/4885 |
| US-20050085522-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | AGTR2, F12, UTS2R | CYP3A4 2833/4885TSHR 1522/4885PIK3CA 3753/4885 |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | XDH, CYP2B6, COX6B1 | CYP3A4 27/4885TSHR 3040/4885PIK3CA 2984/4885 |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | CYP3A4 3545/4885TSHR 3658/4885PIK3CA 27/4885 |
| US-20110124640-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BTK, LYN, ABL1 | CYP3A4 1935/4885TSHR 1212/4885PIK3CA 10/4885 |
| US-20180221379-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK2, SIK3 | CYP3A4 3417/4885TSHR 4752/4885PIK3CA 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.